Q1 FY27 results analysis · August 14, 2026

Rubicon Research Ltd Q1 FY27 Results Analysis: PAT Nearly Doubles, Revenue Surges 51.6%

+95.8%PAT year on year, Rs. 84.78 Cr
Cofacto ResearchPublished August 14, 20262 min readPositive read
Quick summary

Rubicon Research Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 534.34 Cr (+51.60% YoY) and PAT growth of +95.80% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 14, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 534.34 Cr (+51.60% YoY)
PAT (Q1)Rs. 84.78 Cr (+95.80% YoY)
EBITDA margin24.16% (+172 bps YoY)
EPS (Q1)Rs. 5.08 (+82.10% YoY)
Market capRs. 26,779.79 Cr
CMPRs. 1,619.10

Quarter Snapshot

Q1 FY27 consolidated revenue grew 51.6% YoY to Rs.534.34 Cr and PAT nearly doubled to Rs.84.78 Cr, with EBITDA margin of 24.16% above the 22–23% guided band. Operating leverage, lower finance costs and rupee depreciation drove the margin beat, while the Arinna acquisition added two months of revenue. Watch items: Pithampur FDA observations and margin-dilutive subsidiaries.

Key Investment Insights

Key Positives

  • Consolidated revenue grew 51.6% YoY to Rs.534.34 Cr and 4.0% QoQ.
  • EBITDA margin was 24.16%, above the management's 22–23% guidance band and up from 22.44% YoY.
  • PAT grew 95.8% YoY to Rs.84.78 Cr; diluted EPS rose to Rs.5.08 from Rs.2.79.
  • Gross margin improved to 68.38% from 67.06% in Q4 FY26, within the 67–68% target.
  • Finance costs fell 12.5% YoY to Rs.9.29 Cr; borrowings reduced from ~Rs.393 Cr to ~Rs.259 Cr.
  • R&D expense was 11.24% of revenue, within the guided 10–11% range.

Risk Factors

  • Pithampur facility received 2 procedural FDA 483 observations with no closure update in the filing.
  • Subsidiaries are margin-dilutive: consolidated EBITDA margin 24.16% vs standalone 29.18%; subsidiary PBT was a Rs.0.29 Cr drag and PAT contribution was Rs.2.33 Cr.
  • Employee benefits expense rose 47.2% YoY and 25.3% QoQ.
  • IPO proceeds of Rs.805.69 Mn remained unutilised as of 30 June 2026; deployment timeline extended to 31 March 2027.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.